


We are Daiichi Sankyo.

We are dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, we are primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 120 years of scientific expertise and a presence in more than 20 countries, our company and our 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

We are a global pharmaceutical company with over 120 years of scientific expertise

Our European headquarter is located in Munich (Germany). Our European production site in Pfaffenhofen (Germany) contributes significantly to our global production capacity. Products are not only manufactured but also developed there.



Visit our website for more information:
www.daiichi-sankyo.eu

* as of April 2021 ** https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405_5th_MTP_E.pdf

 Daiichi-Sankyo

Passion for Innovation.
Compassion for Patients.™

Our portfolio covers the two main causes of death in Europe:




Our cardiovascular commitment

We care for every heartbeat. Cardiovascular disease (CVD) remains Europe's leading cause of death, responsible for more than 10,000 deaths every day.¹ We have made a long-term commitment to invest and work tirelessly to help and protect patients from CVD so that they can enjoy every precious moment that life offers. We focus on supporting the clinical community and healthcare ecosystems across Europe, today. And beyond providing medicines, we investigate new opportunities to improve care through patient-centric approaches, new technologies and partnerships. Since 2002 more than 40 million² patients across Europe have been treated with our products.

Our oncology commitment

Together for patients, together for those who stand beside them: the cancer burden is estimated to have risen to 1.3 million deaths in 2020.³ Every cancer journey is a unique and personal experience that is very complex and sometimes challenging to fully understand. We know that people living with cancer may also be a mother or father who want to see their children smile. A partner, a friend, a daughter, a son who long to kiss and hug their loved ones. It is with this knowledge that we conduct all our science and research. With passion for true innovation, we seek to transform standards of care and address areas of unmet medical need. We want to create moments that matter – for another warm embrace, another smile or touch.

Our diseases areas

| | | | |
|----------------------|---|---------------------|--|
| Thrombotic disorders |  | Dyslipidaemia |  |
| Hypertension |  | Atrial fibrillation |  |
| Hypercholesterolemia |  | | |

Our diseases areas

| | | | | | |
|---------------|---|---------------------|--|------------------------|--|
| Breast cancer |  | Gastric cancer |  | Colorectal cancer |  |
| Lung cancer |  | Other solid tumours |  | Haematological cancers |  |

Our purpose

To contribute to the enrichment of quality of life around the world.

Our mission

To create innovative pharmaceuticals addressing diverse medical needs.

Our vision

To become an innovative global healthcare company contributing to the sustainable development of society.



Our European values



COMMITMENT

We are committed to striving for success, to show resilience and discipline, and to focus on people.



COURAGE

We have the courage to improve ourselves, to challenge, to think and act differently, and to take the customer's perspective.



COLLABORATION

We collaborate and therefore proactively share, put our team first, and trust each other.



INTEGRITY

We adhere to our values and follow ethical standards to build our reputation.

¹ ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020; 41(1): 111-188.

² Daiichi Sankyo. Company presentation. Data on file.

³ <https://ec.europa.eu/jrc/en/news/2020-cancer-incidence-and-mortality-eu-27-countries>